On Friday, Shares of The McClatchy Company (NYSE:MNI), dropped -3.27% to $1.48, hitting its lowest level.
The McClatchy Company, said the net loss from ongoing operations in the first quarter of 2015 was $11.3 million, or $0.13 per share contrast to a net loss from ongoing operations of $16.1 million, or $0.19 per share, in the first quarter of 2014. The net loss in the first quarter of 2014, counting the impact of suspended operations, was $15.8 million, or $0.18 per share.
The net loss from ongoing operations on an adjusted basis in the first quarter of 2015, not taking into account certain items, was $8.7 million contrast to a net loss from ongoing operations in the first quarter of 2014, adjusted for similar items, of $6.1 million.
In 2014 the company began reporting the wholesale fees paid for certain third-party digital products and services as a reduction of the associated revenues (rather than being recorded as expense). This has no impact on the company’s operating income, operating cash flows or earnings. The most noteworthy of these digital agreements related to Cars.com. Stated results regarding the company’s sales of Cars.com products are influenced by the execution of a new associate agreement with Cars.com on Oct.1, 2014. Under the new associate agreement, the wholesale fees raised, and as a result, net revenues (gross revenues net of wholesale fees) from the sales of Cars.com products in the first three quarters of 2015 are not comparable to net revenues in the first three quarters of 2014.
The McClatchy Company publishes newspapers, and related digital and direct marketing products in the United States. Its newspapers comprise the Miami Herald, The Kansas City Star, The Sacramento Bee, The Charlotte Observer, The (Raleigh) News and Observer, and the (Fort Worth) Star-Telegram.
Shares of SunEdison, Inc. (NYSE:SUNE), declined -3.24% to $26.61, during its last trading session.
SunEdison, declared that is has signed a contract to develop and install a 2.6 megawatt (MW) solar power plant for the town of Winchendon, Mass. on a formerly unusable 12 acre town-owned landfill site.
The landfill site will be converted under Massachusetts’ Solar Renewable Energy Certificates (SREC II) program, which provides preferred incentives for brown field projects.
Winchendon will save up to $8 million in energy costs over the 20 year power purchase agreement and will also receive incremental lease revenue from SunEdison. The solar power plant is projected to save 1,805 tons of carbon dioxide per year, equivalent to the amount of carbon sequestered by 1,479 acres of trees, or taking 380 cars off the road.
SunEdison, Inc. develops, manufactures, and sells silicon wafers to the semiconductor industry. The company operates through three segments: Solar Energy, TerraForm Power, and Semiconductor Materials.
At the end of Friday’s trade, Shares of Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), dwindled -2.80% to $1.3850.
Peregrine Pharmaceuticals, declared the presentation of data from preclinical studies demonstrating the combination of phosphatidylserine (PS) blockade with anti-PD-1 or anti-CTLA-4 immune checkpoint inhibitors promoted strong, localized and improved efficacy in models of melanoma and breast cancer. These data were presented at the 106th Annual Meeting of the American Association for Cancer Research (AACR) being held in Philadelphia, Pennsylvania from April 18-22, 2015. Peregrine’s lead PS-blocking antibody, bavituximab, is presently being evaluated in second-line non-small cell lung cancer (NSCLC) in a Phase III clinical trial named Sunrise.
In a poster titled: “Antibody-mediated phosphatidylserine blockade significantly enhances the efficacy of immune checkpoint blockades in K1735 and B16 mouse melanoma models,” researchers from Peregrine, UT Southwestern Medical Center and the University of California at Irvine presented data assessing the antitumor effect of the combination of PS blockade and anti-CTLA-4 or anti-PD-1 antibodies in preclinical models of melanoma. Both combinations showed significantly superior tumor growth inhibition over single treatment, with many subjects achieving complete tumor regressions. The combination treatment showed significantly greater total and functional tumor-infiltrating CD8+ T, more IL-2- and interferon gamma (IFNγ)-producing splenic T cells, and lower number of splenic myeloid derived suppressor cells myeloid-derived suppressor cells (MDSCs) than did single treatment. In addition, the ratio of M2 to M1 macrophages in the tumor was significantly lower in the combination treatment than that in single treatment. Finally, no toxicity was observed in any of the treatment groups following multiple treatment doses.
In a poster titled: “Targeting of phosphatidylserine by monoclonal antibodies enhances the activity of immune checkpoint inhibitors in breast tumors,” Peregrine researchers presented data demonstrating that PS blockade enhances the anti-tumor activity of combination therapies counting anti-PD-1 antibodies in an immune competent model of breast cancer. Tumor growth inhibition correlates with statistically noteworthy enhances in the infiltration of CD8+ T cells and a reduction of myeloid-derived suppressor cells (MDSCs). The combination of these mechanisms promotes strong and localized anti-tumor responses without the side-effects of systemic immune activation.
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research and development of novel monoclonal antibodies for the treatment and diagnosis of cancer in the United States.
Finally, Vipshop Holdings Limited (NYSE:VIPS), ended its last trade with -3.08% loss, and closed at $28.95.
Vipshop Holdings Limited, declared that the Company has filed its annual report on Form 20-F that comprises its audited financial statements for three years ended December 31, 2014 with the Securities and Exchange Commission on April 24, 2015. The annual report is accessible on the Company’s website at ir.vip.com. Holders of the Company’s securities may request a hard copy of the Company’s annual report free of charge according to the instructions offered on the Company’s website.
Vipshop Holdings Limited, through its auxiliaries, operates as an online discount retailer for various brands in the People’s Republic of China. It offers a range of branded products, counting apparel for women, men, and children; fashion goods; cosmetics; home goods and other lifestyle products; footwear; sportswear and sporting goods; luxury goods; and gifts and miscellaneous products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
